drugset / Trial / NCT05477797
Id and Rd Maintenance Regimens After Induction of Remission in Multiple Myeloma.
RandomizedParallel-groupOpen-labelTreatment
Summary
Newly Diagnosed Myeloma Patients, who achieved efficacy above VGPR (very good PR)after initial treatment were enrolled. Patients were then randomly assigned to Id and Rd groups for maintenance treatment. Therapeutic effectiveness will be reviewed monthly until intolerant side effect or disease progression appear . The follow-up period is approximately 2 years.
Timeline
- Start
- 2023-02-16
- Primary completion
- 2026-01-15
- Completion
- 2026-01-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ixazomib | Unknown | 4 mg | Oral |
| Subject | Lenalidomide | Other / unclassified | 25 mg | — |
| Background | Dexamethasone | Small molecule | 20 mg | Oral |
Indications
No indication recorded.